NNC9204-1706

NNC9204-1706,  or NN9423, is a GLP-1/GIP/glucagon receptor triple agonist made by the Danish pharmaceutical company Novo Nordisk. It was evaluated in a clinical trial. 

It is found that the side effects of this drug include "dose-dependent increases in heart rate and reductions in reticulocyte count, increases in markers of inflammation and hepatic disturbances, and impaired glucose tolerance at the highest dosages", meaning that the drug was declared to have a poor safety profile and discontinued.

References

Category:Chemicals